Free Trial

Perpetual Ltd Buys New Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Viking Therapeutics logo with Medical background

Perpetual Ltd bought a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 958,368 shares of the biotechnology company's stock, valued at approximately $78,586,000. Perpetual Ltd owned 0.87% of Viking Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Massmutual Trust Co. FSB ADV acquired a new stake in shares of Viking Therapeutics in the 1st quarter valued at approximately $25,000. Los Angeles Capital Management LLC acquired a new stake in Viking Therapeutics in the first quarter worth $976,000. Vanguard Group Inc. boosted its position in shares of Viking Therapeutics by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 5,381,904 shares of the biotechnology company's stock worth $100,157,000 after purchasing an additional 97,552 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Viking Therapeutics by 88.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,119,885 shares of the biotechnology company's stock valued at $20,841,000 after buying an additional 525,296 shares during the period. Finally, Virtu Financial LLC increased its position in shares of Viking Therapeutics by 15.1% in the 4th quarter. Virtu Financial LLC now owns 29,394 shares of the biotechnology company's stock valued at $547,000 after buying an additional 3,866 shares in the last quarter. Institutional investors own 76.03% of the company's stock.

Insider Transactions at Viking Therapeutics

In related news, CFO Greg Zante sold 66,756 shares of the firm's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $74.69, for a total value of $4,986,005.64. Following the completion of the transaction, the chief financial officer now directly owns 174,854 shares of the company's stock, valued at $13,059,845.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Viking Therapeutics news, CFO Greg Zante sold 66,756 shares of the business's stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the transaction, the chief financial officer now owns 174,854 shares of the company's stock, valued at $13,059,845.26. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Marianna Mancini sold 281,425 shares of the firm's stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $78.66, for a total value of $22,136,890.50. Following the completion of the sale, the chief operating officer now directly owns 348,508 shares of the company's stock, valued at $27,413,639.28. The disclosure for this sale can be found here. Company insiders own 4.70% of the company's stock.


Analyst Upgrades and Downgrades

Several research analysts have weighed in on VKTX shares. Jefferies Financial Group initiated coverage on Viking Therapeutics in a report on Thursday, March 7th. They set a "buy" rating and a $110.00 target price on the stock. Truist Financial reiterated a "buy" rating and issued a $120.00 price objective on shares of Viking Therapeutics in a research report on Monday. Maxim Group restated a "buy" rating and set a $120.00 target price on shares of Viking Therapeutics in a report on Tuesday, June 4th. StockNews.com upgraded shares of Viking Therapeutics to a "sell" rating in a report on Friday, May 31st. Finally, William Blair restated an "outperform" rating on shares of Viking Therapeutics in a report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Viking Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $112.38.

Get Our Latest Stock Analysis on Viking Therapeutics

Viking Therapeutics Stock Performance

Viking Therapeutics stock traded down $0.21 during mid-day trading on Thursday, reaching $50.43. The company's stock had a trading volume of 2,929,170 shares, compared to its average volume of 4,892,928. Viking Therapeutics, Inc. has a 12 month low of $8.28 and a 12 month high of $99.41. The business's 50 day simple moving average is $65.25 and its 200 day simple moving average is $49.86. The company has a market capitalization of $5.56 billion, a price-to-earnings ratio of -54.23 and a beta of 1.04.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. During the same period in the prior year, the firm posted ($0.25) earnings per share. As a group, sell-side analysts expect that Viking Therapeutics, Inc. will post -1.08 EPS for the current year.

Viking Therapeutics Profile

(Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

See Also

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Should you invest $1,000 in Viking Therapeutics right now?

Before you consider Viking Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.

While Viking Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

How to Navigate Stock Downgrades
CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines